Cytology and Histology of Glandular Lesions - Hong Kong Society of ...
Cytology and Histology of Glandular Lesions - Hong Kong Society of ...
Cytology and Histology of Glandular Lesions - Hong Kong Society of ...
Transform your PDFs into Flipbooks and boost your revenue!
Leverage SEO-optimized Flipbooks, powerful backlinks, and multimedia content to professionally showcase your products and significantly increase your reach.
<strong>Cytology</strong> <strong>and</strong> <strong>Histology</strong> <strong>of</strong><br />
Benign Gl<strong>and</strong>ular <strong>Lesions</strong> <strong>of</strong><br />
the Uterine Cervix<br />
Máire A. Duggan MD, FRCPC,<br />
9 th<br />
Annual Meeting,<br />
<strong>Hong</strong> <strong>Kong</strong> <strong>Society</strong> <strong>of</strong> <strong>Cytology</strong>,<br />
<strong>Hong</strong> <strong>Kong</strong>,<br />
December 5, 2008
Goal<br />
• Know the key cytopathologic <strong>and</strong><br />
histopathologic features <strong>of</strong> usual <strong>and</strong><br />
unusual benign gl<strong>and</strong>ular lesions <strong>of</strong> the<br />
uterine cervix
• Benign <strong>Lesions</strong><br />
– Physiologic<br />
– Iatrogenic<br />
– Inflammatory<br />
– Neoplastic<br />
– Metaplastic<br />
– Hyperplastic<br />
Classification
Cytopathology <strong>of</strong><br />
Gl<strong>and</strong>ular <strong>Lesions</strong><br />
• Variable<br />
• Confounded if more than one pathology<br />
• Diagnoses include<br />
– NILM<br />
• Other: BEC; age>/=40 years<br />
– Atypical gl<strong>and</strong>ular cells<br />
– Adenocarcinoma in situ<br />
– Invasive adenocarcinoma<br />
Chhieng. Clin Lab Med. 2003; 23: 633.
Normal endocervical cells Normal endometrial cells<br />
Cell Features Endocervical Endometrial<br />
Cell size ++ +<br />
Cytoplasm Abundant ++ Variable<br />
Nucleus Oval /elongated Round<br />
DeMay. In: The Pap Test. 2005, 110.
Benign Endometrial Cells<br />
• NILM<br />
– Menstrual<br />
(BEC) in a Pap test<br />
• Highest frequency: day 1-4<br />
• Infrequent after day 14<br />
– Brush artifact <strong>of</strong> LUS<br />
– BEC in Women /=40<br />
Ng. Acta Cytol 1974, 18:356, Gondos. Ann Clin Lab Sci 1977; 7: 486,Chang. Gynecol Oncol 2001; 80: 37.
Exit ball: cytology<br />
Menstrual Endometrium<br />
Key features<br />
•<br />
Stromal cells: cytology<br />
Bloody background<br />
• Groups with central stroma <strong>and</strong> peripheral<br />
gl<strong>and</strong>ular cells<br />
• Hyperchromatic spindle cells<br />
Exit ball: <strong>Histology</strong><br />
Shimizu. Diagn Cytopathol. 2006; 34: 609.
Abraded Endometrium<br />
Key features<br />
•<br />
Biphasic tissue fragments<br />
• Packed spindle cells<br />
• Branching tubular gl<strong>and</strong>s<br />
De Peralta-Venturino. Diagn Cytopathol 1995;12: 263.
Benign Endometrial Cells<br />
in a woman >/=40 years<br />
• Rationale<br />
– Post menopausal: 1.7% endometrial carcinoma<br />
– Symptomatic: 17% endometrial adenocarcinoma<br />
• Currently controversial<br />
– 2-5 fold increase in reporting<br />
– 30% increase in endometrial sampling<br />
– 1% endometrial pathology (0.8% malignant)<br />
– Not cost effective for asymptomatic women<br />
– Post menopausal status <strong>and</strong> symptoms more predictive<br />
Ng. Acta Cytol 1974, 18:356, Kapali. Cancer Cytopathol. 2007; 111:26, Thrall. Cancer Cytopathol.<br />
2005; 105: 207, Beal. Am J Obstet Gynecol. 2007; 196: 568.
AGUS:Atypical Gl<strong>and</strong>ular cells <strong>of</strong><br />
%<br />
35<br />
30<br />
25<br />
20<br />
15<br />
10<br />
5<br />
0<br />
Undetermined Significance<br />
٠Nuclear atypia > benign < malignant<br />
29<br />
AGC: 94 follow up studies<br />
0.3<br />
8.5<br />
11.1<br />
JNCI Workshop. JAMA 1989; 262: 931. JNCI Workshop. Acta Cytol 1993; 37: 115. Schnatz. Obstet<br />
Gynecol 2006; 107:701<br />
1.4 0.7<br />
2.9<br />
2.9<br />
1.2<br />
neoplasm squamous gl<strong>and</strong>ular<br />
Other<br />
Endom hyper<br />
Endom ca<br />
cervix ais<br />
cervix ca<br />
scc<br />
lsil<br />
hsil<br />
all
Terminological Evolution<br />
• Adenocarcinoma in situ (AIS)<br />
– Precursor lesion <strong>of</strong> invasive adenocarcinoma<br />
• Cytologic criteria<br />
– High PPV<br />
– Excellent reproducibility<br />
• Separate category in TBS 2001<br />
• All other AGUS: atypical gl<strong>and</strong>ular cells<br />
Solomon. Acta Cytol 1998; 42: 1, Solomon JAMA. 2002; 287: 2114.
AIS: cytologic criteria<br />
• Arrangements<br />
– 3D crowded aggregates<br />
• Feathering<br />
– Single cells<br />
• Nuclear features<br />
– Altered polarity<br />
– Oval/elongated shape<br />
– Hyperchromasia<br />
– Apoptosis<br />
– Mitoses<br />
Biscotti. Diagn Cytopathol 1997:17; 326.
Adenocarcinoma In Situ:<br />
3 D aggregates, hyperchromasia<br />
Endocervical cells
Adenocarcinoma In Situ:<br />
rosette, feathering, ↑n:c, apoptosis
Adenocarcinoma In Situ:<br />
altered polarity, mitoses, strip
AGC: Atypical Gl<strong>and</strong>ular Cells<br />
• Classified<br />
– Not otherwise specified (NOS)<br />
• Endocervical, endometrial, gl<strong>and</strong>ular<br />
– Favor neoplastic<br />
• Endocervical, endometrial<br />
Solomon JAMA. 2002; 287: 2114, Chhieng . Clin Lan Med 2003; 23: 633, Schnatz. Obstet Gynecol.<br />
2006; 107: 701, Ramsaroop. Diagn Cytopathol2006; 34: 614, Simsir. Cancer Cytopathol. 2003; 99: 323.
•<br />
AGC: cytologic features<br />
Some but not all features present<br />
Cell Feature<br />
Arrangements 3D Aggregates<br />
Rosettes<br />
Strips<br />
Borders Indistinct<br />
Cytoplasm Reduced<br />
Covell. Springer; New York: 2004, 123.
AGC: cytologic features<br />
•<br />
Some but not all features present<br />
Nucleus Feature<br />
Arrangement Crowded<br />
Feathering<br />
Palisading<br />
Size <strong>and</strong> shape Increased <strong>and</strong> Variable<br />
Chromatin Dark<br />
Coarsely granular<br />
Nucleoli Absent or inconspicuous<br />
Mitosis Present<br />
Covell. Springer; New York: 2004, 123.
Atypical Endometrial Cells<br />
Additional features<br />
•<br />
•<br />
•<br />
•<br />
Cells in small 3D groups<br />
-Hyperchromatic<br />
crowded<br />
groups (HCG)<br />
Vacuolated cytoplasm<br />
Hyperchromatic nuclei<br />
Small nucleoli<br />
Covell. Springer; New York: 2004, 123, DeMay. Am J Clin Pathol 2000; 114 suppl 1: s36.
AGC: Atypical Gl<strong>and</strong>ular Cells<br />
• Follow up<br />
– colposcopy, endocervical curettage <strong>and</strong><br />
endometrial biopsy<br />
– HPV testing<br />
• Reproducibility<br />
– poor for cell type <strong>and</strong> diagnosis<br />
• LBC diagnoses more sensitive <strong>and</strong> higher<br />
PPV
AGC: Psammoma<br />
Bodies without Atypia<br />
• Rare occurrence<br />
• <strong>Cytology</strong> features<br />
•<br />
•<br />
Psammoma body<br />
• No cells/single layer <strong>of</strong> benign cells<br />
Etiology<br />
– 50% benign-50% malignant<br />
Kern. Acta Cytol 1991; 35: 81. Nicklin. Gynecol Oncol<br />
2001; 83: 6, Zreik. Obstet Gynaecol 2001; 97: 693.
Benign <strong>Lesions</strong>: classification<br />
• Physiologic<br />
– Arias Stella reaction<br />
• Iatrogenic<br />
– Fallopian tube prolapse<br />
– Drug/procedure associated<br />
• Inflammatory<br />
– IUD
Physiologic: Arias Stella<br />
Reaction<br />
• Hormonally associated proliferative<br />
atypia <strong>of</strong> gl<strong>and</strong>ular epithelium<br />
• Endometrial gl<strong>and</strong>s typically involved<br />
• Endocervical gl<strong>and</strong>s rarely involved<br />
– 9% hysterectomies from pregnant women<br />
• Rarely presents as an abnormal Pap test<br />
Arias Stella. Arch Pathol 1954; 58: 112, Arias Stella. Cancer 1959; 12: 782, Schneider. Acta Cytol 1981; 25: 224..
<strong>Histology</strong>: Arias Stella Reaction<br />
Key pathology<br />
•<br />
Cytoplasmic clearing<br />
• Nuclear enlargement<br />
• Hobnailed nuclei<br />
• Hyperchromasia
<strong>Cytology</strong>:<br />
Arias Stella Reaction<br />
Key features<br />
•<br />
Cells: single/aggregates<br />
•Clear cytoplasm<br />
•<br />
•<br />
•<br />
•<br />
Nuclei: round/oval<br />
Variable n:c ratio<br />
Chromatin: smudgy, granular<br />
Background: inflammatory<br />
Benoit. Diagn Cytopathol 1996; 14: 349.
Arias Stella Reaction:<br />
differential diagnosis<br />
• Clear cell adenocarcinoma, HSIL<br />
• Clues<br />
– History <strong>of</strong> current or recent pregnancy<br />
– <strong>Histology</strong><br />
• Focal lesion, confined to endocervical gl<strong>and</strong>s<br />
• Absent stromal invasion<br />
– <strong>Cytology</strong><br />
• Absent diathesis <strong>and</strong> mitoses<br />
• Single cells, groups rare<br />
• Navicular cells may be present
Iatrogenic: Fallopian Tube<br />
Prolapse<br />
• Rare complication <strong>of</strong> vaginal hysterectomy<br />
• Symptoms<br />
• Dyspareunia<br />
• Vaginal bleeding <strong>and</strong> discharge<br />
• Rarely presents as an abnormal Pap test<br />
• Complications: none<br />
Silverberg. Arch Pathol 1974; 97:100.
Key pathology<br />
•<br />
Inflamed Tubal mucosa<br />
• Regenerative changes<br />
Fallopian Tube Prolapse
Key features<br />
•<br />
Fallopian Tube<br />
Prolapse<br />
Hypercellular smear<br />
• Inflammatory background<br />
• Sheets <strong>and</strong> groups <strong>of</strong> small gl<strong>and</strong>ular cells<br />
• Uniform nuclei.<br />
• Mitoses infrequent
Prolapsed Fallopian Tube:<br />
differential diagnosis<br />
• Well differentiated adenocarcinoma<br />
• Clues<br />
– Previous hysterectomy for benign disease<br />
– <strong>Histology</strong><br />
• Absent stromal invasion<br />
• Absent cell stratification<br />
– <strong>Cytology</strong><br />
• Absent blood <strong>and</strong> diathesis<br />
• Absent nuclear variability <strong>and</strong> mitoses
Iatrogenic: Tamoxifen Therapy<br />
• Small blue cells<br />
– Post menopausal women/Tamoxifen<br />
– Origin: parabasal or reserve cell<br />
• Differential diagnosis<br />
– Metastatic breast carcinoma<br />
– Endometrial carcinoma<br />
• Clues<br />
– History<br />
– Absent diathesis, nuclear variability, mitoses
Small Blue Cell <strong>of</strong><br />
Tamoxifen Therapy<br />
Key features<br />
•<br />
•<br />
•<br />
Loose clusters <strong>of</strong> naked nuclei<br />
Smooth nuclear outlines<br />
Uniform hyperchromasia<br />
Opjorden. Cancer 2001; 93:23, Yang . Arch Pathol Lab Med 2001; 125:1047.
Inflammatory: IUD Changes<br />
• Variable changes<br />
– Type <strong>and</strong> duration <strong>of</strong> use<br />
• Endometrium<br />
– Chronic endometritis<br />
– Regenerative atypia<br />
– Squamous <strong>and</strong> hobnail metaplasia<br />
– Gl<strong>and</strong> atrophy <strong>and</strong> decidualization<br />
Schmidt. Hum Pathol 1982; 13: 878, Buckley. Curr Top Pathol 1994; 86: 307.
<strong>Cytology</strong>:IUD changes<br />
IUD cells<br />
• Possibly endometrial<br />
•High N:C<br />
• Multinucleated<br />
•Nucleoli<br />
Actinomyces<br />
Hypermucinated<br />
endocervical cells<br />
Psammoma body<br />
Gupta. Acta Cytol 1978; 22: 286.
Benign <strong>Lesions</strong>: classification<br />
• Neoplastic<br />
– Endocervical<br />
polyp<br />
– Adenomyoma<br />
– Papillary<br />
aden<strong>of</strong>ibroma<br />
– Villus adenoma<br />
• Metaplastic<br />
– Tubal<br />
– Tuboendometrioid<br />
– Oxyphilic<br />
– Prostatic
Neoplastic: Endocervical Polyp<br />
• Most frequent tumor <strong>of</strong> the cervix<br />
• Gross<br />
– Single lesion<br />
– Round with a smooth surface<br />
– 2-3cm<br />
• Histological Types<br />
– Mucosal<br />
– Stromal<br />
– Vascular<br />
Caroti. Clin Exp Obstet Gynecol. 1988; 15: 108.
Key pathology<br />
•<br />
Fibrovascular core<br />
• Feeder vessel<br />
• Mucinous epithelium<br />
• Squamous metaplasia<br />
Endocervical Polyp
Endocervical Polyp: <strong>Cytology</strong><br />
• Not diagnostic<br />
• Benign or atypical cells<br />
– Enlarged cells <strong>and</strong> nuclei<br />
– Multinucleation<br />
– Hyperchromasia<br />
– Prominent nucleoli<br />
• Inflammation<br />
– Pus <strong>and</strong> blood<br />
• Squamous metaplasia<br />
Ghorab. Diagn Cytopathol 2000; 22: 342.
Metaplasia: Tubo-endometrioid<br />
• Frequent incidental finding<br />
– 31% cone/hysterectomy specimens<br />
• Etiology<br />
– Idiopathic<br />
– Gl<strong>and</strong>ular ectopia<br />
– Repair reaction: laser, 5fu, xrt<br />
– Adenosis: DES<br />
Jonasson . Int J Gynecol Pathol 1992; 11: 89, Robboy. Arch Pathol Lab Med 1977; 101:1, Bernstein .<br />
Obstet Gynecol 1993; 81: 896.
Tubo/endometrioid metaplasia<br />
Key pathology<br />
•<br />
Usually confined to inner 1/3 <strong>of</strong> cervix<br />
•Tubal-ciliated, non ciliated, <strong>and</strong> peg cells<br />
•Endometrioid -non ciliated cells, apical snouts, no peg cells<br />
• Bcl2 positive, p16 focally positive, Ki67
Key pathology<br />
• Sheets or single cells<br />
• Terminal bars/cilia<br />
• Enlarged, polarized nuclei<br />
• Fine chromatin<br />
• Small nucleoli<br />
• Rare mitosis<br />
• Clean background<br />
Tubal Metaplasia:<br />
cytology<br />
Novotny. Acta Cytol 1992: 36; 1, Robboy. Am J Obstet Gynecol 1981; 140: 579.
Hyperplastic: pseudoneoplastic<br />
• Microgl<strong>and</strong>ular hyperplasia<br />
• Endometriosis<br />
• Endocervical hyperplasia<br />
• Mesonephric hyperplasia<br />
• Nabothian<br />
• Tunnel Clusters<br />
• Endosalpingioisis<br />
cysts <strong>and</strong> deep gl<strong>and</strong>s
Hyperplasia: Microgl<strong>and</strong>ular<br />
• Presentation: incidental or polyp<br />
• Frequency: 27% cone/hysterectomy<br />
• Progestin relationship unclear<br />
• Complications<br />
– Atypical/florid<br />
Leslie. Prog Surg Pathol 1984; 5: 95, Young . AJSP 1989; 13: 50, Witkiewicz. Hum Pathol 2005; 35:<br />
154.
Microgl<strong>and</strong>ular Hyperplasia<br />
Key pathology<br />
• Focal/diffuse, superfical/deep proliferation<br />
• Closely packed small tubular gl<strong>and</strong>s<br />
• Mucinous epithelium, reserve cells, squamous metaplasia<br />
• Mitosis:
<strong>Cytology</strong> features<br />
• Sheets <strong>of</strong> enlarged gl<strong>and</strong>ular cells<br />
• Vacuolated cytoplasm<br />
• Mild nuclear enlargement<br />
• Fine chromatin<br />
• Small nucleoli<br />
Microgl<strong>and</strong>ular<br />
Hyperplasia<br />
Yahr. Diagn Cytopathol 1991: 7; 248
Hyperplasia: Endometriosis<br />
• Uncommon<br />
• Etiology<br />
– Post conization/implantation<br />
• Pap test presentation: rare<br />
– Variable: NILM – HSIL – AIS<br />
– Absolute diagnosis very difficult<br />
Baker. Int J Gynecol Pathol 1999; 18: 198.
Cervical Endometriosis<br />
Key pathology<br />
•<br />
Endometrial gl<strong>and</strong>s<br />
• Endometrial stroma<br />
• No atypia
<strong>Cytology</strong> features<br />
• Cell spindling<br />
• Cell uniformity<br />
• Absent diathesis<br />
Endometriosis<br />
Lundeen. Diagn Cytopathol 2002;26:35.
Hyperplasia:Endocervical<br />
• Rare: incidental finding, mucus<br />
discharge, mass lesion<br />
• Proliferation confined to inner half <strong>of</strong><br />
cervix<br />
• Pap test presentation: not reported<br />
• 2 Histological types:<br />
– Lobular-pyloric gl<strong>and</strong> metaplasia (PGM)<br />
– Diffuse laminar hyperplasia (DLEH)<br />
Nucci. AJSP 1999; 23: 886, Jones. AJSP 1991; 15: 1123.
Lobular Hyperplasia<br />
Key pathology<br />
• Rounded proliferation <strong>of</strong><br />
small gl<strong>and</strong>s<br />
• Duct centred<br />
• Pseudocribriform pattern<br />
• Bl<strong>and</strong> mucinous epithelium<br />
Immunopr<strong>of</strong>ile<br />
• PAS positive<br />
• p16 positive<br />
• HIK1083 positive<br />
• HPV DNA negative<br />
• CEA negative<br />
Hashi. Int J Gynecol Pathol 2006; 25: 187. Nara. Gynecol Oncol 2007; 106: 289.
Key Pathology<br />
•<br />
Diffuse Laminar<br />
Endocervical Hyperplasia<br />
Circumscribe gl<strong>and</strong>ular proliferation<br />
• Chronic inflammatory infiltrate<br />
• Benign endocervical gl<strong>and</strong>s
Mesonephric Remnants<br />
• Wolffian duct remnants: lateral wall<br />
– 22% adults<br />
• Pap test presentation: rare<br />
– Clusters <strong>of</strong> cuboidal cells<br />
• Complications<br />
– Hyperplasia<br />
• Proliferation>6mm: diffuse/lobular/ductal<br />
– Occasionally transmural<br />
– Carcinoma<br />
Ferry . AJSP 1990; 14: 1100, Jones. Gynecol Oncol 1993; 49: 41. Hejmadi. Cytopathol 2005; 16:<br />
240.
Mesonephric Hyperplasia<br />
Key pathology<br />
• Small tubular gl<strong>and</strong>s<br />
• No intracellular mucin or glycogen<br />
• PAS positive luminal, colloid like secretion
The End<br />
Thank you for your attention
<strong>Cytology</strong> <strong>and</strong> <strong>Histology</strong> <strong>of</strong><br />
Malignant Gl<strong>and</strong>ular <strong>Lesions</strong><br />
<strong>of</strong> the Uterine Cervix<br />
Máire A. Duggan MD, FRCPC,<br />
9 th Annual Meeting,<br />
<strong>Hong</strong> <strong>Kong</strong> <strong>Society</strong> <strong>of</strong> <strong>Cytology</strong>,<br />
<strong>Hong</strong> <strong>Kong</strong>,<br />
December 6, 2008
Goal<br />
• Know the key cytopathologic <strong>and</strong><br />
histopathologic features <strong>of</strong> usual <strong>and</strong><br />
unusual malignant gl<strong>and</strong>ular lesions <strong>of</strong><br />
the uterine cervix
• Malignant <strong>Lesions</strong><br />
Classification<br />
– Premalignant lesions<br />
• Adenocarcinoma in situ: AIS<br />
• Endocervical gl<strong>and</strong>ular dysplasia: EGD<br />
• Stratified mucin producing intraepithelial lesion:<br />
SMILE<br />
– Adenocarcinoma
Gl<strong>and</strong>ular Premalignancy<br />
• Precursor lesions <strong>of</strong> adenocarcinoma<br />
– AIS: good evidence<br />
– Dysplasia: poor evidence<br />
• AIS incidence: 0.6/100,000<br />
– CIN III: x50 more frequent<br />
• AIS prevalence: increasing
AIS: risk factors<br />
• 50% AIS: concomitant SIL<br />
• Risk factors similar to SIL<br />
• HPV 16 <strong>and</strong> 18<br />
• Multiple sexual partners<br />
• OCP<br />
• Early onset sexual activity<br />
• Low socio-economic status<br />
Zaino. Int J Gynecol Pathol 2002; 21: 314.
AIS: clinical features<br />
• Mean age: 29 years<br />
• Symptoms<br />
– None, discharge, abnormal Pap test<br />
• Location: 65% T zone<br />
• Mostly unifocal<br />
• Colposcopy: no specific pattern
AIS<br />
• Frequency: 10% <strong>of</strong> gl<strong>and</strong>ular malignancies<br />
• Histological types: not clinically significant<br />
– Mucinous<br />
– Intestinal<br />
– Adenosquamous<br />
- Clear cell<br />
- Endometrioid<br />
- Ciliated<br />
Friedell. Cancer 1953; 6: 887, Schlesinger. Int J Gynecol Pathol 1999;18:1.
AIS<br />
Key pathology<br />
• Normal gl<strong>and</strong>ular architecture<br />
• Decreased mucin<br />
• Stratified columnar cells<br />
• Hyperchromatic nuclei<br />
• Mitoses<br />
• Absent stromal invasion
AIS: HPV status <strong>and</strong> IHC<br />
• HPV DNA<br />
– 66% (40-90%) positive<br />
– HPV 16 <strong>and</strong> 18<br />
– Predominance <strong>of</strong> HPV 18<br />
• Antibody positive<br />
– CEA ( 70%) <strong>and</strong> Steroid receptors<br />
– P16 <strong>and</strong> p53<br />
– Ki67: high index (>30%)<br />
• Antibody negative<br />
– Vimentin <strong>and</strong> bcl2<br />
McCluggage. J Clin Pathol 2003; 56: 164.. Wells. Int J Gynecol Pathol 2002;21: 360. Duggan. Int J<br />
Gynecol Pathol 1994; 13: 143, Liang. Int J Gynecol Pathol 2007; 26: 71.
AGC <strong>and</strong> HSIL<br />
• Approximately 16% <strong>of</strong> AGC in follow up<br />
= HSIL<br />
• Reasons<br />
– Co-incidental lesions<br />
• AIS <strong>and</strong> HSIL: 50%<br />
– Gl<strong>and</strong>ular mimics<br />
• HSIL in endocervical gl<strong>and</strong>s
AIS<br />
AIS <strong>and</strong> HSIL: 2 cell types<br />
HSIL
Pattern A<br />
Pattern B<br />
HSIL involving<br />
endocervical gl<strong>and</strong>s<br />
Mattosinho. Acta Cytol 2003; 47: 154.<br />
Selvaggi. Acta Cytol 1994:38; 687.
• Uncommon lesion<br />
SMILE<br />
• Resembles SIL with full thickness<br />
cytoplasmic vacuolization<br />
• Described in association with cervical<br />
adenocarcinoma<br />
• Also associated with HSIL, AIS or<br />
squamous cell carcinoma<br />
Park. AJSP. 2000; 24: 1414 McCluggage Pathol 2006; 39: 97.
Key pathology<br />
• Dysplastic nuclei<br />
• Mucin vacuoles<br />
•Mitoses<br />
SMILE<br />
<strong>Cytology</strong> features<br />
• Not reported
Endocervical Dysplasia<br />
• Controversial lesion<br />
– No outcome studies<br />
• Alternate terminologies<br />
– Low CGIN: UK<br />
– Superficial (early) AIS<br />
• Investigation<br />
– HPV testing<br />
– P16 positive<br />
– Steroid receptor positive<br />
Zaino. Int J Gynecol Pathol 2002; 21: 314, Brown. J Clin Pathol 1986; 39: 22, Witkiewicz. AJSP<br />
2005; 29: 1609, Liang. Int J Gynecol Pathol 2007; 26: 71.
Endocervical dysplasia: criteria<br />
• Hyperchromatic<br />
nuclei<br />
• Occasional mitoses<br />
• Minimal stratification<br />
• AIS in one gl<strong>and</strong><br />
• Other criteria<br />
• Management<br />
– controversial<br />
McCluggage. J Clin Pathol 2003; 56: 164.
Adenocarcinoma: epidemiology<br />
• 20-25% cervical carcinomas<br />
• Mean age at presentation<br />
– Microinvasive adenocarcinoma: 39-44 years<br />
– Invasive adenocarcinoma: 44-54 years<br />
• Incidence increasing in Canada <strong>and</strong> elsewhere<br />
– 1994-96: 1.83/100,000<br />
• 41% relative increase in 22 years<br />
• Higher Pap test false negative rate due to sampling error<br />
Liu. CMAJ 2001; 164: 1, Wang. Cancer 2004; 100: 1035, Herzog. Am J Obstet Gynecol. 2007; Dec: 566 .
Adenocarcinoma: risk factors<br />
• Sexual behavior<br />
– Early age <strong>of</strong> onset <strong>of</strong> sexual activity<br />
– Lifetime number <strong>of</strong> sexual partners<br />
– Early age <strong>of</strong> first birth <strong>and</strong> increasing parity<br />
• Oral contraceptives<br />
• Obesity <strong>and</strong> body fat distribution<br />
• No association with cigarette smoking<br />
Green. Br J Cancer 2003; 89: 2078, Lacey. Cancer 2003; 98: 814, Castellsague. J NCI. 2006; 98: 303,<br />
Berrington de Gonzalez. Int J Cancer. 2007; 120: 885.
Adenocarcinoma: risk factors<br />
• Human Papilloma Virus (odds ratio=81)<br />
– 88% HPV DNA positive<br />
– Types 16/18 in 82%<br />
• Genetic<br />
• Type 16 predominant in endometrioid <strong>and</strong> VGA<br />
• Type 18=16 or slight predominance in others<br />
– Ovarian carcinoma<br />
– Peutz Jegher’s syndrome<br />
An. Mod Pathol. 2005 18: 528, Duggan. Hum Pathol 1995; 26: 319, Pirog . Am J Clin Pathol 2000;<br />
157: 1055, Altekruss . Am J Obstet Gynecol 2003; 188: 657, Castellsague. J NCI. 2006; 98: 303.
Adenocarcinoma: classification<br />
• 57% Mucinous<br />
• 30% Endometrioid<br />
• 11% Clear cell<br />
• 2% Rare types<br />
– Minimal deviation<br />
– Serous<br />
– Mesonephric<br />
– Well differentiated villogl<strong>and</strong>ular<br />
Wright. Springer Verlag, 2002.
Classification System<br />
Deficiencies<br />
• Variable frequency <strong>of</strong> endometrioid<br />
– 7-50%<br />
• Interobserver agreement<br />
– Endocervical, endometrioid, clear cell,<br />
serous: moderate-good<br />
– Mixed carcinomas: fair-poor<br />
– Villogl<strong>and</strong>ular, adenosquamous: poor<br />
Young. Int J Gynecol Pathol 2002; 21: 212, Alfsen. Gynecol Oncol 2003; 90: 282..
Mucinous Adenocarcinoma<br />
• Synchronous premalignancy<br />
– 66% AIS<br />
– 16% HSIL<br />
• Synchronous mucinous tumors <strong>of</strong> ovary <strong>and</strong><br />
fallopian tube<br />
– Primary or metastatic<br />
• 3 morphologic types<br />
– Endocervical, intestinal, signet ring<br />
• Pure<br />
• Mixed<br />
Wang. Gynecol Oncol. 2006; 103: 541.
Endocervical adenocarcinoma<br />
Key pathology<br />
• Complex racemose gl<strong>and</strong>s<br />
• Surface <strong>and</strong> intraluminal papillae<br />
• Pale granular cytoplasm<br />
• Brisk mitotic activity<br />
• Apoptotic bodies<br />
Young. Histopathol 2002; 41: 185.
Endocervical adenocarcinoma<br />
• Mostly neutral mucin: content variable<br />
– Pas/al blue: red/purple mixed cytoplasmic stain<br />
– Mucicarmine: cytoplasmic positivity<br />
• Antibody positive<br />
– CEA : cytoplasmic<br />
– P16 positive: diffuse <strong>and</strong> strong<br />
• Antibody negative<br />
– Vimentin<br />
– Estrogen receptor<br />
Wells. Int J Gynecol Pathol 2002; 21: 360.
Endocervical adenocarcinoma<br />
Pas/al blue<br />
Vimentin<br />
CEA<br />
p16
<strong>Cytology</strong>:endocervical<br />
adenocarcinoma<br />
• Hypercellular smears<br />
• Cells<br />
– Single<br />
– Sheets<br />
– Clusters<br />
• Cell features <strong>of</strong> AIS<br />
• Additional features<br />
– Perinuclear clearing<br />
– Macronucleoli<br />
– Tumor Diathesis<br />
Covell. Springer; New York: 2004, 141.
Intestinal adenocarcinoma<br />
Key pathology<br />
• Gl<strong>and</strong>s <strong>and</strong> papillae<br />
• Pseudostratified mucin poor cells<br />
• Goblet cells<br />
Young <strong>and</strong> Clement. Histopathol 2002; 41: 185.
Signet ring carcinoma<br />
Key pathology<br />
• Signet ring cells<br />
• Pure form is rare<br />
• Usually mixed with other types<br />
Young. Histopathol 2002; 41: 185.
Endometrioid Adenocarcinoma<br />
• Resembles endometrial counterpart<br />
• Synchronous premalignancy<br />
– Higher compared to non endometrioid carcinomas<br />
• 81% AIS<br />
• 54% HSIL<br />
• Difficult to distinguish from mucin poor<br />
mucinous carcinomas<br />
• Lower frequency <strong>of</strong> squamous differentiation<br />
• Better prognosis than mucinous carcinoma<br />
Wang. Gynecol Oncol. 2006; 103: 541.
Endometrioid adenocarcinoma<br />
Key pathology<br />
• Gl<strong>and</strong>ular architecture<br />
• Benign squamous differentiation<br />
• Stratified, oval nuclei<br />
• No cytoplasmic mucin<br />
Young. Histopathol 2002; 41: 185.
Endometrioid carcinoma<br />
<strong>Cytology</strong> features<br />
• Similar to mucinous<br />
carcinoma
Clear cell Carcinoma<br />
• DES exposed<br />
• Young women<br />
• Location<br />
– Ectocervical<br />
• HPV status<br />
– Usually negative<br />
– Rare cases HPV 31<br />
positive<br />
• Sporadic<br />
• Post menopausal<br />
women<br />
• Location<br />
– Endo or ectocervical<br />
Waggoner. Obstet Gynecol 1994; 84: 404.
Young. Histopathol 2002; 41: 185.<br />
Clear cell Carcinoma<br />
Key pathology<br />
• Solid, tubulocystic, papillary<br />
• Glycogenated clear cytoplasm<br />
• Intracystic mucin<br />
• Hobnail cells
Clear cell Carcinoma<br />
<strong>Cytology</strong> features<br />
• Large cells<br />
• Abundant cytoplasm<br />
• Round nucleus<br />
• Prominent nucleolus
• Rare tumor<br />
– 3 types<br />
• Associations<br />
Minimal Deviation<br />
Adenocarcinoma<br />
–Adenoma malignum<br />
–Endometrioid<br />
–Clear cell<br />
– Not HPV related: 1 report <strong>of</strong> type 16 <strong>and</strong> 18+<br />
– Lobular endocervical hyperplasia (PGM)<br />
– AIS with a gastric immunophenotype<br />
– Adenoma malignum (AM)<br />
• Mucinous ovarian tumors<br />
• SCTAT<br />
• Peutz Jeghers Syndrome<br />
Gilks. Am J Surg Pathol 1989; 13: 717, Hart . Int J Gynecol Pathol 2002; 21: 327, Fukishima . Jpn J<br />
Clin Oncol 1990 ; 20: 407, Mikami. Mod Pathol. 2004; 17: 962.
Adenoma Malignum<br />
• Symptoms<br />
– Pr<strong>of</strong>use watery discharge/bleeding<br />
• Difficult on cytology <strong>and</strong> small biopsies<br />
• <strong>Cytology</strong> features<br />
– Irregular sheets <strong>of</strong> benign gl<strong>and</strong>ular cells<br />
– Rare malignant cells with large nucleoli<br />
• Prognosis<br />
– Worse than mucinous carcinoma<br />
Voselgang. Diagn Cytopathol 1995; 13: 146.
Adenoma malignum<br />
Key pathology<br />
• Atypical gl<strong>and</strong>s: shape, size, location<br />
• Desmoplasia near outpouchings<br />
• Single layer <strong>of</strong> low grade mucinous cells<br />
• Rare gl<strong>and</strong> with malignant cells
Adenoma Malignum versus<br />
Normal or Benign Endocervix<br />
Stain Adenoma Malignum Normal or Benign<br />
PAS/Al Blue Mostly red Purple/ violet<br />
HIK1083-PGM + -*<br />
CEA + -<br />
P16 30% + -<br />
Alpha SMA Increased + stroma - stroma<br />
ER - stroma + stroma<br />
*positive staining in lobular hyperplasia<br />
Hayashi. Am J Surg Pathol 2000; 24: 559, Mikami. Mod Pathol 2004; 17: 962. Ischimura. Int J<br />
Gynecol Pathol 2001; 20: 220, Mikami. Gynecol Oncol 1999; 74: 501, McCluggage. Pathol<br />
2007; 39: 97.
*ph=2.5<br />
Adenoma Malignum: Pas Al Blue*<br />
Adenoma Malignum Normal Gl<strong>and</strong><br />
Hayashi. Am J Surg Pathol. 2000; 24: 559.
Serous Carcinoma<br />
• <strong>Histology</strong> similar to ovarian <strong>and</strong><br />
endometrial counterparts<br />
• Metastatic spread should be excluded<br />
• Outcome<br />
– Stage 1 = Stage 1 endocervical<br />
adenocarcinoma<br />
– Advanced stage: rapidly fatal<br />
N<strong>of</strong>ech-Mozes. Int J Gynecol Cancer. 2006; 16 Suppl 1: 286.
Serous carcinoma<br />
Key pathology<br />
• Complex papillary proliferation<br />
• Stratification <strong>and</strong> tufting<br />
• High grade nuclei<br />
• P53 positive, CEA negative<br />
Zhou. Am J Surg Pathol 1998; 22:130.
Serous Carcinoma<br />
<strong>Cytology</strong> features<br />
• Single cells<br />
• Sheets<br />
• Tight balls<br />
• Malignant features obvious<br />
• Psammoma bodies<br />
Chang. Cancer 1999; 87: 5.
Mesonephric carcinoma<br />
• Rare tumor<br />
– 30 documented cases<br />
• Arise from mesonephric duct remnants<br />
• Gross appearance<br />
– Cervical mass<br />
• HPV negative<br />
• Outcome<br />
– More indolent than mucinous carcinoma<br />
Clement. Am J Surg Pathol 1995; 19: 1158, Hart. Int J Gynecol Pathol 2002; 21: 327, Pirog. Am J<br />
Pathol 2000; 157: 1055.
Mesonephric carcinoma<br />
Key pathology<br />
• Variable pattern: mostly ductal<br />
• Retiform, tubular, sex cord, spindle cell<br />
• Eosinophilic mucinous secretion<br />
• Mesonephric remnants
Mesonephric carcinoma:<br />
immunohistochemistry<br />
• Pattern similar to mesonephric remnants<br />
• Negative staining<br />
– mCEA, CTK 20, ER/PR<br />
• Positive staining<br />
– EMA, CTK 7, CAM 5.2, CD10, Vimentin,<br />
Calretinin, Inhibin, p16<br />
• CEA, CD10, <strong>and</strong> vimentin pattern is<br />
controversial<br />
Silver. Am J Surg Pathol 2001; 25: 379, Clement. Am J Surg Pathol 1995; 19: 1158, Ordi. Am J<br />
Surg Pathol 2001; 25: 1540 , Tringler. Hum Pathol 2004; 35: 689.
Well Differentiated<br />
Villogl<strong>and</strong>ular Adenocarcinoma<br />
• Rare tumor <strong>of</strong> young women<br />
– Average age: 35<br />
• Presentation: vaginal bleeding/exophytic mass<br />
• May be mixed with other types <strong>of</strong> carcinoma<br />
• HPV status<br />
– 100% type16/18 positive<br />
– Mostly type 16<br />
• Prognosis usually excellent<br />
Young. Cancer 1989; 63: 1773, Jones. Int J Gynecol Pathol 1993; 12: 1. Jones. Int J Gynecol<br />
Pathol 2000; 19: 110. Fadare. Virchows Arch 2005; 447: 883.
Well differentiated<br />
villogl<strong>and</strong>ular adenocarcinoma<br />
Key pathology<br />
• Papillary architecture<br />
• Minimal cytological atypia<br />
• Minimal stromal invasion<br />
• No desmoplasia
Well differentiated<br />
villogl<strong>and</strong>ular<br />
adenocarcinoma: cytology<br />
• Not specific<br />
• Atypical gl<strong>and</strong>ular cells<br />
– Papillary fragments<br />
– Nuclear crowding<br />
– Subtle atypia<br />
• High false negative rate<br />
Chang. Cancer 1999; 87: 5.
Secondary Adenocarcinoma<br />
• Genital tract<br />
– Endometrial carcinoma<br />
– Ovarian, tubal <strong>and</strong> peritoneal<br />
• Extragential sites<br />
– Rare<br />
• Breast<br />
• Colorectal<br />
• Gastric<br />
Zaino. Int J Gynecol Pathol 2001; 21: 1, Mazur. Cancer 1984; 53: 1978.
Endometrial carcinoma<br />
• Stage II tumors<br />
– IIa: Surface cancerization<br />
– IIb: Stromal invasion<br />
• Tumor source<br />
– Direct spread<br />
– Surface metastases<br />
– Embolic<br />
Scurry. Int J Gynecol Oncol 2000; 10: 497.
Stage IIa<br />
Stage II endometrial<br />
carcinoma: histology<br />
Stage IIb
Endometrial endometrioid carcinoma: cytology<br />
Key Pathology<br />
• Watery diathesis<br />
• Crowded groups<br />
• Prominent nucleoli<br />
• Ingested PMNs
Cervical Primary versus Stage<br />
II Endometrial Carcinoma<br />
Antibody Cervix Endometrium<br />
ER/PR 83% - 70% +<br />
CEA 86% + 89% -<br />
Vimentin 86% - 59% +<br />
P16 100% +<br />
strong/diffuse<br />
30%+<br />
Moderate/patchy<br />
Castrillon. Int J Gynecol Pathol 2001; 21: 4, McCluggage. Pathology 2007; 39: 97.
Stage II Endometrial Carcinoma<br />
mCEA<br />
Vimentin<br />
PTEN: tumor suppressor gene<br />
• Endometrial carcinoma: somatic mutations<br />
• Expression is diminished<br />
• Cervical adenocarcinoma<br />
• Expression retained<br />
p16<br />
El-Mansi. Int J Gynecol Cancer 2006; 16: 1254.
Extrauterine genital tract primaries<br />
Transtubal migration:<br />
serous ovarian carcinoma<br />
• Dissemination pathways<br />
• Direct spread<br />
• Embolic spread<br />
• Transtubal migration<br />
Olsen . Obstet Gynecol 2001; 78: 71.
Metastatic Breast<br />
Carcinoma<br />
Pap test<br />
Endocervical curettage<br />
• Frequency increasing<br />
• longer survival<br />
• Lobular more frequent than ductal<br />
• Pap test: rare malignant cells<br />
• <strong>Histology</strong>: isolated metastasis<br />
Ng. Acta Cytol 1974; 18: 108, Hepp. Cancer Invest 1999; 17: 468.
Metastatic colonic carcinoma<br />
Key cytology features<br />
• Dirty background<br />
• Gl<strong>and</strong>ular groups<br />
• Palisading <strong>of</strong> basal nuclei<br />
Lemoine. Cancer 1986; 57: 2002, Nakagami. Jpn J Clin Oncol 1999; 29:640.
The End<br />
Thank you for inviting me
Benign <strong>and</strong> Malignant Gl<strong>and</strong>ular <strong>Lesions</strong> <strong>of</strong> the<br />
Uterine Cervix<br />
Máire A. Duggan MD, FRCPC<br />
<strong>Hong</strong> <strong>Kong</strong> <strong>Society</strong> <strong>of</strong> <strong>Cytology</strong> Annual Meeting<br />
<strong>Hong</strong> <strong>Kong</strong><br />
December 7, 2008<br />
References<br />
Alfsen GC et al. Reproducibility <strong>of</strong> classification in non-squamous cell carcinomas <strong>of</strong> the<br />
uterine cervix. Gynecol Oncol 2003; 90:282-89.<br />
Altekruss SF et al. Comparison <strong>of</strong> human papilloma virus genotypes, sexual <strong>and</strong> reproductive<br />
risk factors <strong>of</strong> cervical adenocarcinoma <strong>and</strong> squamous cell carcinoma northeastern United States.<br />
Am J Obstet Gynecol 2003; 188:657-63.<br />
An HJ et al. Prevalence <strong>of</strong> human papillomavirus DNA in various histological subtypes <strong>of</strong><br />
cervical adenocarcinoma: a population based study. Mod Pathol. 2005; 18: 528-34.<br />
Arias-Stella J. A topographic study <strong>of</strong> uterine epithelial atypia associated with chorionic tissue:<br />
demonstration <strong>of</strong> alteration in the endocervix. Cancer 1959; 12:782-790.<br />
Arias-Stella J. Atypical endometrial changes associated with the presence <strong>of</strong> chorionic tissue.<br />
Arch Pathol 1954; 54: 112-128.<br />
Baker PM et al. Superficial endometriosis <strong>of</strong> the uterine cervix: a report <strong>of</strong> 20 cases <strong>of</strong> a process<br />
that may be confused with endocervical gl<strong>and</strong>ular dysplasia or adenocarcinoma in situ. Int J<br />
Gynecol Pathol 1999; 18:198-205.<br />
Beal HN et al. Endometrial cells identified in cervical cytology in woman ≥40 years <strong>of</strong> age:<br />
criteria for appropriate endometrial evaluation, Am J Obstet Gynecol June 2007; 568.e1 –<br />
568.e6.<br />
Benoit JL, Kini SR. “Arias-Stella Reaction” – like changes in endocervical gl<strong>and</strong>ular epithelium<br />
in cervical smears during pregnancy <strong>and</strong> post-partum states. A potential diagnostic pitfall.<br />
Diagnostic Cytopathol 1996; 14:349-355.<br />
Bernstein J et al. Development <strong>of</strong> vaginal adenosis following combined 5-F-U <strong>and</strong> carbon<br />
dioxide laser treatments for diffuse vaginal condylomatosis. Obstet Gynecol 1993; 81:896-898.<br />
Berrington de Gonzales A, <strong>and</strong> Green J. Comparison <strong>of</strong> risk factors for invasive squamous cell<br />
carcinoma <strong>and</strong> adenocarcinoma <strong>of</strong> the cervix: Collaborative reanalysis <strong>of</strong> individual data on<br />
1
8,097 women with squamous cell carcinoma <strong>and</strong> 1,374 women with adenocarcinoma from 12<br />
epidemiological studies. Int J Cancer 2007 ;120: 885-91.<br />
Biscotti CV et al. Endocervical adenocarcinoma in situ: an analysis <strong>of</strong> cellular features. Diagn<br />
Cytopathol 1997; 17:326-332.<br />
Brown LJ <strong>and</strong> Wells M. Cervical gl<strong>and</strong>ular atypia associated with squamous intraepithelial<br />
lesions: a premalignant lesion? J Clin Pathol 1986; 39:22-28.<br />
Buckley CH. The pathology <strong>of</strong> intra-uterine contraceptive devices. Curr Top Pathol 1994;<br />
86:307-330.<br />
Caroti S <strong>and</strong> Siliotti F. Cervical polyps: a colpo-cyto-histological study. Clin Exp Obstet<br />
Gynecol 1988; 15:108-115.<br />
Castellsague X et al. Worldwide human papillomavirus etiology <strong>of</strong> cervical adenocarcinoma <strong>and</strong><br />
its c<strong>of</strong>actors: implications for screening <strong>and</strong> prevention. J Natl Cancer Inst. 2006; 98: 303-15.<br />
Castrillon D et al. Distinction between endometrial <strong>and</strong> endocervical adenocarcinoma: an<br />
immunohistochemical study. Int J Gynecol Pathol 2001; 21:4-10.<br />
Chang A et al. Cytologically benign endometrial cells in the Papanicolaou smears <strong>of</strong><br />
postmenopausal women. Gynecol Oncol 2001; 80:37-43.<br />
Chang WC et al. Cytologic features <strong>of</strong> villogl<strong>and</strong>ular adenocarcinoma <strong>of</strong> the uterine cervix:<br />
comparison with typical endocervical adenocarcinoma with a villogl<strong>and</strong>ular component <strong>and</strong><br />
papillary serous carcinoma. Cancer 1999; 87:5-11.<br />
Chhieng DC <strong>and</strong> Cangiarella JF. Atypical gl<strong>and</strong>ular cells. Clin Lab Med. 2003 Sep;23(3):633-<br />
57.<br />
Clement PB et al. Malignant mesonephric neoplasms <strong>of</strong> the uterine cervix. Am J Surg Pathol<br />
1995; 19:1158-71.<br />
Covell J et al. Epithelial gl<strong>and</strong>ular abnormalities. In: The Betheseda System for reporting<br />
cervical cytology. Definitions, Criteria <strong>and</strong> Explanatory Notes. Editors: Solomon D <strong>and</strong> Nayar R.<br />
2 nd edition. Springer Verlag. New York, USA. 2004,141-47.<br />
Covell JL et al. Epithelial abnormalities: gl<strong>and</strong>ular. In: The Bethesda System for Reporting<br />
Cervical <strong>Cytology</strong>. Definitions, Criteria <strong>and</strong> Explanatory notes. 2 nd Edition. Editors: Solomon D.<br />
<strong>and</strong> Nayar R. Springer, New York, USA. 2004; 123-156.<br />
de Peralta-Venturino MN et al. Endometrial cells <strong>of</strong> the "lower uterine segment" (lus) in cervical<br />
smears obtained by endocervical brushings: a source <strong>of</strong> potential diagnostic pitfall. Diagn<br />
Cytopathol 1995; 12:263-271.<br />
2
DeMay R. Hyperchromatic crowded groups: pitfalls in Pap smear diagnosis. Am J Clin Pathol<br />
2000; 114, Suppl 1: S36-43.<br />
DeMay R. <strong>Cytology</strong> <strong>of</strong> the gl<strong>and</strong>ular epithelium. In: The Pap Test. ASCP Press Chicago, USA.<br />
2005; 110-116.<br />
Duggan MA et al. Adenocarcinoma in situ <strong>of</strong> the endocervix; human papillomavirus<br />
determination by dot blot hybridization <strong>and</strong> polymerase chain reaction amplification. Int J<br />
Gynecol Pathol 1993; 13:143-149.<br />
Duggan MA et al. The human papilloma virus status <strong>of</strong> invasive cervical adenocarcinoma: a<br />
clinicopathological <strong>and</strong> outcome analysis. Hum Pathol 1995; 26: 319-25<br />
El-Mansi MT <strong>and</strong> Williams AR. Evaluation <strong>of</strong> PTEN expression in cervical adenocarcinoma by<br />
tissue microarray. Int J Gynecol Cancer 2006; 16:1254-60.<br />
Fadare O <strong>and</strong> Zheng W. Well-differentiated papillary villogl<strong>and</strong>ular adenocarcinoma <strong>of</strong> the<br />
uterine cervix with a focal high-grade component: is there a need for reassessment? Virchows<br />
Arch. 2005; 447:883-7.<br />
Ferry JA <strong>and</strong> Scully RE. Mesonephric Reminants, hyperplasia <strong>and</strong> neoplasia in the uterine<br />
cervix. A study <strong>of</strong> 49 cases. Am J Surg Pathol 1990; 14:1100-1111.<br />
Friedell G <strong>and</strong> McKay D. Adenocarcinoma In Situ <strong>of</strong> the endocervix. Cancer 1953; 6:887-897.<br />
Fukushima N et al. The detection <strong>of</strong> human papilloma virus (HPV) in a case <strong>of</strong> minimal<br />
deviation adenocarcinoma <strong>of</strong> the uterine cervix (adenoma malignum) using in situ hybridization.<br />
Jpn J Clin Oncol 1990; 20:407-12.<br />
Ghorab Z et al. Endocervical reactive atypia: a histological cytologic study. Diagn Cytopathol<br />
2000; 22:342-346.<br />
Gilks CB et al. Adenoma malignum (minimal deviation adenocarcinoma) <strong>of</strong> the uterine cervix:<br />
a clinico-pathological <strong>and</strong> immunohistochemical analysis <strong>of</strong> 26 cases. Am J Surg Pathol 1989;<br />
13:717-29.<br />
Gondos B <strong>and</strong> King EB. Significance <strong>of</strong> endometrial cells in cervicovaginal smears. Ann Clin<br />
Lab Sci 1977; 7:486-490.<br />
Green J et al. Risk factors for adenocarcinoma <strong>and</strong> squamous cell carcinoma <strong>of</strong> the cervix in<br />
women aged 20-44 years: the UK national case control study <strong>of</strong> cervical cancer. Br J Cancer<br />
2003; 89:2078-86.<br />
Gupta P et al. Epithelial atypias associated with intrauterine contraceptive devices (IUD). Acta<br />
Cytol 1978; 22:286-291.<br />
3
Hart WR . Symposium Part II. Special types <strong>of</strong> adenocarcinoma <strong>of</strong> the uterine cervix. Am J<br />
Gynecol Pathol 2002; 21:327-46.<br />
Hashi A et al. p161NK4a overexpression independent <strong>of</strong> human papillomavirus infection in<br />
lobular endocervical gl<strong>and</strong>ular hyperplasia. Int J Gynecol Pathol. 2006; 25:187-94.<br />
Hayashi I et al. Reappraisal <strong>of</strong> orthodox histochemistry for the diagnosis <strong>of</strong> minimal deviation<br />
adenocarcinoma <strong>of</strong> the cervix. Am J Surg Pathol 2000; 24:559-62.<br />
Hejmadi RK et al. Mesonephric hyperplasia can cause abnormal cervical smears: report <strong>of</strong> three<br />
cases with review <strong>of</strong> literature. Cytopathology. 2005; 16:240-3.<br />
Hepp HH et al. Breast cancer metastasis to the uterine cervix: analysis <strong>of</strong> a rare event. Cancer<br />
Invest 1999; 17:468-73.<br />
Herzog TJ; Monk BJ Reducing the burden <strong>of</strong> gl<strong>and</strong>ular carcinomas <strong>of</strong> the uterine cervix, Am J<br />
Obstet Gynecol December 2007; 566 – 571<br />
Ischimura T et al. Immunohistochemical expression <strong>of</strong> gastric mucin <strong>and</strong> p53 in minimal<br />
deviation adenocarcinoma <strong>of</strong> the uterine cervix. Int J Gynecol Pathol 2001; 20:220-26.<br />
Jonasson JG et al. Tubal metaplasia <strong>of</strong> the uterine cervix: a prevalence study in patients with<br />
gynecologic pathologic findings. Int J Gynecol Pathol. 1992;11:89-95.<br />
Jones MA et al. Diffuse laminar endocervical gl<strong>and</strong>ular hyperplasia. Am J Surg Pathol<br />
1991;15:1123-129.<br />
Jones MA et al. Mesonephric reminant Hyperplasia <strong>of</strong> the Cervix: A clinicopatholgic analysis <strong>of</strong><br />
14 cases. Gynecol Oncol 1993; 49:41-47,<br />
Jones MW et al. Well-differentiated villogl<strong>and</strong>ular adenocarcinoma <strong>of</strong> the uterine cervix. A<br />
clinico-pathological study <strong>of</strong> 24 cases. Am J Gynecol Pathol 1993; 12:1-7.<br />
Jones MW et al. Well-differentiated villogl<strong>and</strong>ular adenocarcinoma <strong>of</strong> the uterine cervix:<br />
oncogene/tumor suppressor gene alterations <strong>and</strong> human papilloma virus genotyping. Int J<br />
Gynecol Pathol 2000; 19:110-17.<br />
Kapali M et al. Routine endometrial sampling <strong>of</strong> asymptomatic premenopausal women shedding<br />
normal endometrial cells in papanicolaou tests is not cost effective. Cancer Cytopathol 2007;<br />
111: 26-33.<br />
Kern SB. Prevalence <strong>of</strong> psammoma bodies in Papanicolaou-stained cervicovaginal smears.<br />
Acta Cytol 1991; 35:81-8.<br />
Lacey JV et al. Obesity as a potential risk factor for adenocarcinoma <strong>and</strong> squamous cell<br />
carcinomas <strong>of</strong> the uterine cervix. Cancer 2003; 89:814-21.<br />
4
Lemoine R et al. Epithelial tumors metastatic to the uterine cervix. Cancer 1986; 57: 2002-05.<br />
Leslie KO <strong>and</strong> Silverberg SG. Microgl<strong>and</strong>ular hyperplasia <strong>of</strong> the cervix: unusual clinical <strong>and</strong><br />
pathological presentations <strong>and</strong> their differential diagnosis. Prog Surg Pathol 1984; 5:95-114.<br />
Liang J et al. Utility <strong>of</strong> p16INK4a, CEA, Ki67, P53 <strong>and</strong> ER/PR in the differential diagnosis <strong>of</strong><br />
benign, premalignant, <strong>and</strong> malignant gl<strong>and</strong>ular lesions <strong>of</strong> the uterine cervix <strong>and</strong> their relationship<br />
with Silverberg scoring system for endocervical gl<strong>and</strong>ular lesions. Int J Gynecol Pathol<br />
2007;26:71-5.<br />
Liu S et al. Cervical Cancer: The increasing incidence <strong>of</strong> adenocarcinoma <strong>and</strong> adenosquamous<br />
carcinoma in younger women. CMAJ 2001; 164:1-5.<br />
Lundeen SJ et al. Abnormal cervicovaginal smears due to endometriosis: a continuing problem.<br />
Diagn Cytopathol 2002; 26:35-40.<br />
Masatoshi Nara et al. Lobular endocervical gl<strong>and</strong>ular hyperplasia as a presumed precursor <strong>of</strong><br />
cervical adenocarcinoma independent <strong>of</strong> human papillomavirus infection, Gyne Oncol 2007;<br />
106:289 – 298.<br />
Mattosinho de Castra Ferraz Mola G et al. Atypical gl<strong>and</strong>ular cells <strong>of</strong> undetermined<br />
significance. Cytologic predictive value for gl<strong>and</strong>ular involvement in high grade squamous<br />
intraepithelial lesions. Acta Cytol 2003; 47:154-158.<br />
Mazur MT et al. Metastases to the female genital tract: analysis <strong>of</strong> 325 cases. Cancer 1984;<br />
53:1978-84.<br />
McCluggage WG. Endocervical gl<strong>and</strong>ular lesions: controversial aspects <strong>and</strong> ancillary<br />
techniques. J Clin Pathol 2003; 56:164-173.<br />
McCluggage WG. Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology<br />
2007; 39:97-111.<br />
Mikami Y et al. Florid endocervical gl<strong>and</strong>ular hyperplasia with intestinal <strong>and</strong> pyloric gl<strong>and</strong><br />
metaplasia: worrisome benign mimic <strong>of</strong> adenoma malignum. Gynecol Oncol 1999; 74:501-11.<br />
Mikami Y et al. Gastro intestinal immuno phenotype in adenocarcinoma <strong>of</strong> the uterine cervix<br />
<strong>and</strong> dilated gl<strong>and</strong>ular lesions. A possible link between lobular endocervical gl<strong>and</strong>ular<br />
hyperplasia/pyloric gl<strong>and</strong> metaplasia <strong>and</strong> adenoma malignum. Mod Pathol 2004; 17:962-72.<br />
Nakagami K et al. Uterine cervix metastasis from rectal carcinoma, a case report <strong>and</strong> a review <strong>of</strong><br />
the literature. Jpn J Clin Oncol 1999; 29:640-42.<br />
National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal<br />
cytological diagnoses. JAMA. 1989;262:931-4<br />
5
National Cancer Institute Workshop. The Bethesda System for reporting cervical/vaginal<br />
cytological diagnoses: revised after the second National Cancer Institute Workshop, April 29-30,<br />
1991.Acta Cytol. 1993; 37;115-24<br />
Ng AB et al. Significance <strong>of</strong> endometrial cells in the detection <strong>of</strong> endometrial carcinoma <strong>and</strong> its<br />
precursors. Acta Cytol 1974; 18: 356-61.<br />
Ng AB et al. The cellular manifestations <strong>of</strong> extra uterine cancer. Acta Cytol 1974; 18:107-17.<br />
Nicklin JL et al. The significance <strong>of</strong> psammoma bodies in cervical cytology smears. Gynecol<br />
Oncol 2001; 83:6-9.<br />
Nieuwenhuizen L et al. Endometrial <strong>and</strong> endocervical secretion: the search for histochemical<br />
differentiation. Anal Quant Cytol Histol 2006; 28:87-96.<br />
N<strong>of</strong>ech-Mozes S et al. Immunohistochemical characterization <strong>of</strong> endocervical papillary serous<br />
carcinoma. Int J Gynecol Cancer 2006; 16 Suppl 1:286-92.<br />
Novotny DB et al. Tubal metaplasia. a frequent potential pitfall in the cytologic dianosis <strong>of</strong><br />
gl<strong>and</strong>ular dysplasia in cervical smears. Acta Cytol 1992; 36:1-10.<br />
Nucci MR et al. Lobular endocervical gl<strong>and</strong>ular hyperplasia, not otherwise specified. Am J Surg<br />
Pathol 1999; 23:886-91.<br />
Oliva E et al. Tubal <strong>and</strong> tubo-endometroid metaplasia <strong>of</strong> the uterine cervix. Am J Clin Path<br />
1995; 103:618-623.<br />
Olsen TG et al. Primary peritoneal carcinoma presenting on routine Papanicolaou smear.<br />
Gynecol Oncol 2000; 78:71-73.<br />
Opjorden SL et al. Small cells in cervical-vaginal smears <strong>of</strong> patients treated with tamoxifen.<br />
Cancer 2001; 93:23-28.<br />
Ordi J et al. Mesonephric adenocarcinoma <strong>of</strong> the uterine corpus: CD 10 expression as evidence<br />
<strong>of</strong> mesonephric differentiation. Am J Surg Pathol 2001; 25:1540-45.<br />
Park JJ et al. Stratified mucin producing intraepithelial lesions <strong>of</strong> the cervix: adenosquamous or<br />
columnar cell neoplasia? Am J Surg Pathol 2000; 24:1414-1419.<br />
Pirog EC et al. Prevalence <strong>of</strong> human papilloma virus DNA in different histological subtypes <strong>of</strong><br />
cervical adenocarcinoma. Am J Pathol 2000; 157:1055-62.<br />
Ramsaroop R <strong>and</strong> Chu I. Accuracy <strong>of</strong> diagnosis <strong>of</strong> atypical gl<strong>and</strong>ular cells – conventional <strong>and</strong><br />
Thinprep. Diagn Cytopathol 2006; 34: 614-9.<br />
Robboy SJ et al. Dysplasia <strong>and</strong> cytologic findings in 4,589 young women enrolled in<br />
diethylstilbestrol-adenosis (DESAD) Project. Am J Obstet Gynecol 1981;140:579-86.<br />
6
Schlesinger C <strong>and</strong> Silverberg S. Endocervical adenocarcinoma in situ <strong>of</strong> tubal type <strong>and</strong> its<br />
relation to atypical tubal metaplasia. Int J Gynecol Pathol 1999; 18:1-4.<br />
Schmidt WA. IUDs, inflammation, <strong>and</strong> infection: assessment after 2 decades <strong>of</strong> IUD use. Hum<br />
Pathol 1982; 13:878-881.<br />
Schnatz PF et al. Clinical significance <strong>of</strong> atypical gl<strong>and</strong>ular cells on cervical cytology. Obstet<br />
Gynecol 2006 Mar; 107: 701-8.<br />
Schneider V. Arias-Stella reaction <strong>of</strong> the endocervix: frequency <strong>and</strong> location. Acta Cytol<br />
1981;25: 224-228.<br />
Scurry J et al. Histologic study <strong>of</strong> patterns <strong>of</strong> cervical involvement in Figo stage II endometrial<br />
carcinoma. Int J Gynecol Cancer 2000; 10:497-02.<br />
Selvaggi SM. Cytologic features <strong>of</strong> squamous cell carcinoma in situ involving endocervial<br />
gl<strong>and</strong>s in endocervical cytobrush. Acta Cytol 1994; 38:687-692.<br />
Shimizu K et al. Endometrial gl<strong>and</strong>ular <strong>and</strong> stromal breakdown, part 1: cytomorphological<br />
appearance. Diagn Cytopathol. 2006; 34:609-13.<br />
Shintaku M et al. Adenocarcinoma <strong>of</strong> the uterine cervix with choriocarcinomatous <strong>and</strong> hepatoid<br />
differentiation: report <strong>of</strong> a case. Int J Gynecol Pathol 2000; 19:174-78.<br />
Silver SA et al. Mesonephric adenocarcinomas <strong>of</strong> the uterine cervix: a study <strong>of</strong> 11 cases with<br />
immunohistochemistry findings. Am J Surg Pathol 2001; 25:379-87.<br />
Silverberg SG <strong>and</strong> Frable WJ. Prolapse <strong>of</strong> fallopian tube into vaginal vault after hysterectomy.<br />
Histopathology, cytopathology <strong>and</strong> differential diagnosis. Arch Pathol 1974; 97:100-103.<br />
Simsir A et al. Gl<strong>and</strong>ular cell atypia on Papanicolaou smears: interobserver variability in the<br />
diagnosis <strong>and</strong> prediction <strong>of</strong> cell <strong>of</strong> origin. Cancer Cytopathol. 2003; 99:323-30.<br />
Solomon D et al. ASCUS <strong>and</strong> AGUS Criteria. International Academy <strong>of</strong> <strong>Cytology</strong> Task Force<br />
Summary. Diagnostic cytology towards the 21 st century, an international expert conference <strong>and</strong><br />
tutorial. ACTA Cytol 1998; 42:16-24.<br />
Solomon D et al. The 2001 Bethesda System: Terminology for Reporting Cervical <strong>Cytology</strong>.<br />
JAMA 2002; 287: 2114-2119.<br />
Suh KS <strong>and</strong> Silverberg SG. Tubal metaplasia <strong>of</strong> the uterine cervix. Int J Gynecol Pathol 1990;<br />
9:122-128.<br />
Thrall MJ et al. Significance <strong>of</strong> benign endometrial cells in Papanicolaou tests from women > 40<br />
years. Cancer Cytopathol 2005; 105: 207-216.<br />
7
Tringler B et al. Evaluation <strong>of</strong> p16 <strong>and</strong> pRB expression in cervical squamous <strong>and</strong> gl<strong>and</strong>ular<br />
neoplasia. Hum Pathol 2004; 35:689-96.<br />
Voselgang PJ et al. Exfoliative cytology <strong>of</strong> adenoma malignum (minimal deviation<br />
adenocarcinoma ) <strong>of</strong> the uterine cervix. Diagn Cytopathol 1995; 13:146-50.<br />
Waggoner SE et al. Human papilloma virus detection <strong>and</strong> p53 expression in clear cell<br />
adenocarcinoma <strong>of</strong> the vagina <strong>and</strong> cervix. Obstet Gynecol 1994; 84:404-08.<br />
Wang SS et al. Cervical cancer <strong>and</strong> squamous cell carcinoma incidence trends among white<br />
women <strong>and</strong> black women in the United States for 1976 –2000. Cancer 2004; 100:1035-44.<br />
Wang SS et al. Pathological characteristics <strong>of</strong> cervical adenocarcinoma in a multi-center USbased<br />
study. Gynecol Oncol 2006; 103:541-6.<br />
Wells M <strong>and</strong> Brown LJR. Symposium Part IV. Investigative approaches to endocervical<br />
pathology. Int J Gynecol Pathol 2002; 21:360-367.<br />
Witkiewicz A et al. Superficial (early) endocervical adenocarcinoma in situ: a study <strong>of</strong> 12 cases<br />
<strong>and</strong> comparison to conventional AIS. Am J Surg Pathol. 2005; 29:1609-14.<br />
Witkiewitcz AK et al. Microgl<strong>and</strong>ular hyperplasia: a model for the de novo emergence <strong>and</strong><br />
evolution <strong>of</strong> endocervical reserve cells. Hum Pathol 2005; 36: 154-161.<br />
Wright TC et al. Carcinoma <strong>and</strong> other tumors <strong>of</strong> the cervix. In: Blaustein’s Pathology <strong>of</strong> the<br />
Female Genital Tract. 5 th edition. Editor Kurman RJ. Springer, New York, USA. 2002: 325-81.<br />
Yahr LJ <strong>and</strong> Lee KE. Cytologic findings in microgl<strong>and</strong>ular hyperplasia <strong>of</strong> the cervix. Diagn<br />
Cytopathol 1991; 7:248-251.<br />
Yang YJ et al. The small blue cell dilemma associated with tamoxifen therapy. Arch Pathol Lab<br />
Med 2001; 125:1047-1050.<br />
Young RH <strong>and</strong> Clement PB. Endocervical adenocarcinoma <strong>and</strong> its variants: their morphology<br />
<strong>and</strong> differential diagnosis. Histopathol 2002; 41:185-07.<br />
Young RH <strong>and</strong> Scully RE. Atypical forms <strong>of</strong> microgl<strong>and</strong>ular hyperplasia <strong>of</strong> the cervix<br />
simulating carcinoma. Am J Surg Pathol 1989; 13:50-56.<br />
Young RH <strong>and</strong> Scully RE. Invasive adenocarcinoma <strong>and</strong> related tumors <strong>of</strong> the uterine cervix.<br />
Semin Diagn Pathol 1990; 7: 205-27.<br />
Young RH <strong>and</strong> Scully RE. Villogl<strong>and</strong>ular papillary adenocarcinoma <strong>of</strong> the uterine cervix. A<br />
Clinicopathological Analysis <strong>of</strong> 13 Cases. Cancer 1989; 63:1773-79.<br />
Young RH <strong>and</strong> Scully RE. Uterine carcinomas simulating microgl<strong>and</strong>ular hyperplasia. A report<br />
<strong>of</strong> six cases. Am J Surg Pathol 1992; 16:1092-97.<br />
8
Young RH. Simple clefts, complex problems; reflections on gl<strong>and</strong>ular lesions <strong>of</strong> the uterine<br />
cervix. J Gynecol Pathol 2002; 21:212-16.<br />
Zaino R. The fruits <strong>of</strong> our labors. Distinguishing endometrial from endocervical<br />
adenocarcinoma. Int J Gynecol Pathol 2001; 21:1-3.<br />
Zaino RJ. Symposium Part 1: Adenocarcinoma In situ, gl<strong>and</strong>ular dysplasia, <strong>and</strong> early invasive<br />
adenocarcinoma in situ <strong>of</strong> the uterine cervix. Int J Gynecol Pathol 2002; 21:314-26.<br />
Zhou C et al. Papillary serous carcinoma <strong>of</strong> the uterine cervix. a clinico-pathologic study <strong>of</strong> 17<br />
cases. Am J Surg Pathol 1998; 22:113-20.<br />
Zreik TG <strong>and</strong> Rutherford TJ. Psammoma bodies in cervicovaginal smears. Obstet Gynecol<br />
2001; 97:693-95.<br />
9